Trimtech Therapeutics
Cambridge biotech developing targeted protein degraders for neurodegenerative and inflammatory disease.
Last refreshed: 14 July 2026 · Appears in 1 active topic
Can pharma board seats push Trimtech's degrader platform to the clinic faster?
Timeline for Trimtech Therapeutics
Raised a £25m Series A extension, the Bank's largest-ever direct life-sciences cheque
UK Startups and Innovation: Alchemab wins Bank's record £25m chequeMentioned in: Jobs plan targets the lab-skills gap
UK Startups and Innovationraised extended seed round
UK Startups and Innovation: J&J backs Trimtech seed to GBP35.6mWhat is Trimtech Therapeutics working on?
Who led Trimtech Therapeutics' seed extension?
How much has Trimtech Therapeutics raised in total?
Background
Trimtech Therapeutics extended its seed round to GBP35.6 million in June 2026 after Johnson & Johnson Innovation (JJDC) and BGF added a further $14 million and took board seats.
Founded in Cambridge in 2023 by Leo James of the MRC Laboratory of Molecular Biology and Will McEwan of the UK Dementia Research Institute, the company designs small-molecule targeted protein degraders that tag disease-causing proteins for the cell's own disposal system rather than simply blocking them. Its original GBP25 million seed round, led by Cambridge Innovation Capital in 2025, drew Eli Lilly, Pfizer Ventures and M Ventures among others.
Pharma majors taking board seats rather than just writing cheques signals confidence that Trimtech's degrader platform could reach the clinic for neurodegenerative and inflammatory disease, an area where conventional blocking drugs have struggled. The round adds to a cluster of Cambridge protein-degradation biotechs drawing sustained corporate venture interest.
